Vascular Gate in Neuroendocrine Cancers Limits Immunotherapy Efficacy
Recent research published in the journal Cell reveals a significant mechanism driving resistance to immunotherapy in small cell lung cancer and other neuroendocrine cancers. Scientists have identified a blood-brain barrier-like vascular gate that effectively blocks immune cells from entering tumor sites, thereby hindering the effectiveness of current treatments. This biological barrier prevents CD8+ T cells, which are crucial for attacking cancer cells, from infiltrating the tumor microenvironment. The study highlights that targeting specific proteins, namely IGF1R or IGFBP5, can disrupt this vascular gate. By inhibiting these proteins, researchers observed a substantial boost in CD8+ T cell infiltration into the tumors. Consequently, this enhanced infiltration significantly improves the efficacy of anti-PD1 therapy, a common form of immunotherapy. These findings offer promising new avenues for overcoming treatment resistance in aggressive neuroendocrine cancers. The discovery suggests that combining existing immunotherapies with agents targeting IGF1R or IGFBP5 could lead to better clinical outcomes for patients suffering from these difficult-to-treat malignancies, marking a potential breakthrough in oncological research and personalized medicine strategies.
Wire timeline
Vascular Gate in Neuroendocrine Cancers Limits Immunotherapy Efficacy
Recent research published in the journal Cell reveals a significant mechanism driving resistance to immunotherapy in small cell lung cancer and other neuroendocrine cancers. Scientists have identified a blood-brain barrier-like vascular gate that effectively blocks immune cells from entering tumor sites, thereby hindering the effectiveness of current treatments. This biological barrier prevents CD8+ T cells, which are crucial for attacking cancer cells, from infiltrating the tumor microenvironment. The study highlights that targeting specific proteins, namely IGF1R or IGFBP5, can disrupt this vascular gate. By inhibiting these proteins, researchers observed a substantial boost in CD8+ T cell infiltration into the tumors. Consequently, this enhanced infiltration significantly improves the efficacy of anti-PD1 therapy, a common form of immunotherapy. These findings offer promising new avenues for overcoming treatment resistance in aggressive neuroendocrine cancers. The discovery suggests that combining existing immunotherapies with agents targeting IGF1R or IGFBP5 could lead to better clinical outcomes for patients suffering from these difficult-to-treat malignancies, marking a potential breakthrough in oncological research and personalized medicine strategies.
Cell